Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ROS1 | P08922 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | FRK | P42685 | 1/20 | 0.57 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.57 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.57 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.57 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460456 | 1.00 | PARP1 (1.00) | PARP1PLK4MAP4K4EGFRROS1 | |
| SCHEMBL29959688 | 1.00 | PARP1 (1.00) | PARP1PLK4MAP4K4EGFRROS1 | |
| Hydrochloric Acid SCHEMBL29933479 | 0.98 | PARP1 (0.96) | PARP1PLK4MAP4K4EGFRROS1 | |
| Hydrochloric Acid SCHEMBL18094592 | 0.98 | PARP1 (0.96) | PARP1PLK4MAP4K4EGFRROS1 | |
| SCHEMBL29256793 | 0.93 | PARP1 (0.87) | PARP1PLK4MAP4K4EGFRROS1 | |
| Fumaric Acid SCHEMBL18094591 | 0.90 | PARP1 (0.81) | PARP1PLK4MAP4K4EGFRROS1 | |
| Fumaric Acid SCHEMBL18094590 | 0.90 | PARP1 (0.81) | PARP1PLK4MAP4K4EGFRROS1 | |
| Quinoline SCHEMBL28083721 | 0.90 | PARP1 (0.81) | PARP1PLK4MAP4K4EGFRROS1 | |
| SCHEMBL29761212 | 0.84 | PARP1 (0.73) | PARP1PLK4MAP4K4EGFRROS1 | |
| SCHEMBL28199876 | 0.84 | PARP1 (0.73) | PARP1PLK4MAP4K4EGFRROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-10-16 | — | — | US | disclosed |
| EP-4556473-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025091127-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2025-05-08 | — | — | WO | disclosed |
| EP-4549440-A1 | CLASS OF PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| US-20240376126-A1 | PRMT5 INHIBITOR AND THE USE THEREOF | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2024059216-A2 | 6,6 SOUTHWESTERN CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-113527021-B | Preparation method of formamide compound | 大连理工大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-110526866-B | Synthesis method of 2-quinolinone compounds | 上海交通大学 | 2022-10-25 | — | — | CN | disclosed |
| EP-4055013-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | PARP1 454/4885PLK4 2687/4885MAP4K4 2898/4885 |
| US-20240376126-A1 | PRMT5 INHIBITOR AND THE USE THEREOF | PRMT5, PRMT1, PRMT6 | PARP1 347/4885PLK4 1407/4885MAP4K4 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.